MedTrace Logo

Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study

NCT03174457 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-10-21

No results posted yet for this study

Summary

The aim of the study is to prospectively evaluate the safety and efficacy of micafungin when prescribed for prophylaxis or treatment of fungal infections in different real-world clinical conditions and centers, in pediatric patients in Asia/Oceania.

Conditions

  • Invasive Fungal Infections

Interventions

DRUG

Micafungin

Intravenous

Sponsors & Collaborators

  • Astellas Pharma Singapore Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma Singapore Pte. Ltd.

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-21
Primary Completion
2018-05-31
Completion
2018-05-31
FDA Drug
Yes

Countries

  • Hong Kong
  • Singapore
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03174457 on ClinicalTrials.gov